RESUMEN
BACKGROUND: . Intravitreal administration of topotecan shows activity against tumor vitreous seeding in the conservative treatment of retinoblastoma, a malignant tumor originated in the retina of small children. Adequate storage of the intravitreal topotecan solution would allow immediate availability for patients at health care institutions. The goal of the work was to address the stability of the intravitreal topotecan formulation upon reconstitution. MATERIALS AND METHODS: . Intravitreal topotecan solutions were reconstituted (at a concentration of 0.2 mg topotecan in 1 mL saline solution vehicle, aliquoted in 1 mL plastic syringes) and stored either frozen or at room temperature for different times. Topotecan content was analyzed at time zero and at different conditions using a high performance liquid chromatography method to quantify topotecan lactone (active) and to detect its pH-dependent hydrolysis product, the open carboxylate. RESULTS: . We found that intravitreal topotecan syringes remained stable at room temperature at least for 24 h, at least for 167 days upon stored frozen at -20°C, and up to 8 h after thawing at day 6. The degradation carboxylate product did not appear in the analyzed thawed samples during the whole study. CONCLUSIONS: . This study confirms the stability of frozen intravitreal topotecan syringes and will help optimize the use of this chemotherapy modality at institutions with low resources. Storage of aliquots will also help reduce personnel exposure to chemotherapy at hospital pharmacies.
Asunto(s)
Estabilidad de Medicamentos , Almacenaje de Medicamentos/normas , Inhibidores de Topoisomerasa I/química , Inhibidores de Topoisomerasa I/metabolismo , Topotecan/química , Topotecan/metabolismo , Humanos , Inyecciones Intravítreas , Inhibidores de Topoisomerasa I/análisis , Topotecan/análisisRESUMEN
We investigated controlled blood-brain barrier (BBB) disruption using a low-frequency clinical transcranial MRI-guided focused ultrasound (TcMRgFUS) device and evaluated enhanced delivery of irinotecan chemotherapy to the brain and a rat glioma model. Animals received three weekly sessions of FUS, FUS and 10 mg/kg irinotecan, or irinotecan alone. In each session, four volumetric sonications targeted 36 locations in one hemisphere. With feedback control based on recordings of acoustic emissions, 98% of the sonication targets (1045/1071) reached a pre-defined level of acoustic emission, while the probability of wideband emission (a signature for inertial cavitation) was than 1%. BBB disruption, evaluated by mapping the R1 relaxation rate after administration of an MRI contrast agent, was significantly higher in the sonicated hemisphere (P < 0.01). Histological evaluation found minimal tissue effects. Irinotecan concentrations in the brain were significantly higher (P < 0.001) with BBB disruption, but SN-38 was only detected in <50% of the samples and only with an excessive irinotecan dose. Irinotecan with BBB disruption did not impede tumor growth or increase survival. Overall these results demonstrate safe and controlled BBB disruption with a low-frequency clinical TcMRgFUS device. While irinotecan delivery to the brain was not neurotoxic, it did not improve outcomes in the F98 glioma model.
Asunto(s)
Antineoplásicos/farmacocinética , Barrera Hematoencefálica , Irinotecán/farmacocinética , Imagen por Resonancia Magnética/métodos , Sonicación/métodos , Inhibidores de Topoisomerasa I/farmacocinética , Animales , Antineoplásicos/administración & dosificación , Antineoplásicos/análisis , Antineoplásicos/uso terapéutico , Edema Encefálico/etiología , Neoplasias Encefálicas/tratamiento farmacológico , Femenino , Glioma/tratamiento farmacológico , Irinotecán/administración & dosificación , Irinotecán/análisis , Irinotecán/uso terapéutico , Masculino , Microburbujas , Proyectos Piloto , Profármacos/administración & dosificación , Profármacos/análisis , Profármacos/farmacocinética , Profármacos/uso terapéutico , Púrpura/etiología , Distribución Aleatoria , Ratas , Ratas Endogámicas F344 , Ratas Sprague-Dawley , Sonicación/efectos adversos , Sonicación/instrumentación , Inhibidores de Topoisomerasa I/administración & dosificación , Inhibidores de Topoisomerasa I/análisis , Inhibidores de Topoisomerasa I/uso terapéuticoRESUMEN
Irinotecan (IRT), the pro-drug of SN-38, has exhibited potent cytotoxicity against various tumors. In order to enhance the anti-tumor effect of IRT, we prepared IRT-loaded PLGA nanoparticles (IRT-PLGA-NPs) by emulsion-solvent evaporation method. Firstly, IRT-PLGA-NPs were characterized through drug loading (DL), entrapment efficiency (EE), particle size, zeta potential, transmission electron microscopy (TEM), and differential scanning calorimetry (DSC). We next studied the in vitro release characteristics of IRT-PLGA-NPs. Finally, the pharmacokinetics and pharmacodynamics profiles of IRT-PLGA-NPs were investigated. The results revealed that IRT-PLGA-NPs were spherical with an average size of (169.97 ± 6.29) nm and its EE and DL were (52.22 ± 2.41)% and (4.75 ± 0.22)%, respectively. IRT-PLGA-NPs could continuously release drug for 14 days in vitro. In pharmacokinetics studies, for pro-drug IRT, the t1/2ß of IRT-PLGA-NPs was extended from 0.483 to 3.327 h compared with irinotecan solution (IRT-Sol), and for its active metabolite SN-38, the t1/2ß was extended from 1.889 to 4.811 h, which indicated that IRT-PLGA-NPs could prolong the retention times of both IRT and SN-38. The pharmacodynamics results revealed that the tumor doubling time, growth inhibition rate, and specific growth rate of IRT-PLGA-NPs were 2.13-, 1.30-, and 0.47-fold those of IRT-Sol, respectively, which demonstrated that IRT-PLGA-NPs could significantly inhibit the growth of tumor. In summary, IRT-PLGA-NPs, which exhibited excellent therapeutic effect against tumors, might be used as a potential carrier for tumor treatment in clinic.
Asunto(s)
Antineoplásicos/síntesis química , Irinotecán/síntesis química , Nanopartículas/química , Tamaño de la Partícula , Copolímero de Ácido Poliláctico-Ácido Poliglicólico/síntesis química , Animales , Antineoplásicos/administración & dosificación , Antineoplásicos/análisis , Materiales Biocompatibles/administración & dosificación , Materiales Biocompatibles/análisis , Materiales Biocompatibles/síntesis química , Rastreo Diferencial de Calorimetría/métodos , Línea Celular Tumoral , Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/análisis , Portadores de Fármacos/síntesis química , Evaluación Preclínica de Medicamentos/métodos , Irinotecán/administración & dosificación , Irinotecán/análisis , Ratones , Nanopartículas/administración & dosificación , Nanopartículas/análisis , Copolímero de Ácido Poliláctico-Ácido Poliglicólico/administración & dosificación , Copolímero de Ácido Poliláctico-Ácido Poliglicólico/análisis , Inhibidores de Topoisomerasa I/administración & dosificación , Inhibidores de Topoisomerasa I/análisis , Inhibidores de Topoisomerasa I/síntesis química , Carga Tumoral/efectos de los fármacos , Carga Tumoral/fisiologíaRESUMEN
Rhamnus davurica Pall. (R. davurica) has been used as a traditional medicine for many years in China and abroad and shown a wide spectrum of biological activities. Previously, we reported the phytochemical fingerprinting profile of R. davurica, its distinct anti-proliferative activities against HT-29 and SGC-7901 cell lines, and the topoisomerase I (Top I) ligands based on bio-affinity ultrafiltration and HPLC-MS (UF-HPLC-MS). Nevertheless, among the 32 peaks detected in the fingerprinting profile, the common bioactive constituents responsible for the anti-inflammatory and anti-proliferative activities in the extracts remain elusive. To further explore the specific responsible components for their diversified activities and their potential action targets/mechanisms, the method based on bio-affinity UF-HPLC-MS using therapeutic targets like Top I and cyclooxygenase 2 (COX-2) was established to rapidly screen and identify the ligands binding to these known target enzymes. As a result, 12 components were revealed as potential Top I ligands along with 11 components as potential COX-2 ligands, where several components were revealed to possess both activities. Further validations of these bioactive components have also been conducted and confirmed their highlighted activities. This integrated method of UF-HPLC-MS exhibits high efficiency in rapidly screening for multi-target bioactive components responsible for multiple pharmacological effects from the complex natural products and could be very useful to explain the complex action mechanisms of herb medicines in a complex multi-component and multi-target mode at the molecular level. Graphical abstract Schematic diagram of UF-HPLC-MS assay to screen for Top I and COX-2 ligands. The principle of the assay usually involves the following steps: incubation, ultrafiltration, and identification.
Asunto(s)
Antiinflamatorios/análisis , Antiinflamatorios/farmacología , Antineoplásicos/análisis , Antineoplásicos/farmacología , Proliferación Celular/efectos de los fármacos , Rhamnus/química , Antiinflamatorios/aislamiento & purificación , Antineoplásicos/aislamiento & purificación , Línea Celular Tumoral , Cromatografía Líquida de Alta Presión/métodos , Ciclooxigenasa 2/metabolismo , Inhibidores de la Ciclooxigenasa 2/análisis , Inhibidores de la Ciclooxigenasa 2/aislamiento & purificación , Inhibidores de la Ciclooxigenasa 2/farmacología , ADN-Topoisomerasas de Tipo I/metabolismo , Descubrimiento de Drogas , Flavonoides/análisis , Flavonoides/aislamiento & purificación , Flavonoides/farmacología , Humanos , Neoplasias/tratamiento farmacológico , Espectrometría de Masa por Ionización de Electrospray/métodos , Inhibidores de Topoisomerasa I/análisis , Inhibidores de Topoisomerasa I/aislamiento & purificación , Inhibidores de Topoisomerasa I/farmacología , Ultrafiltración/métodosRESUMEN
This paper describes the synthesis of a novel series of acridine thiosemicarbazones through a two-step reaction between various isothiocyanates and hydrazine followed by treatment with acridin-9-carbaldehyde. The properties of this series of seven new derivatives are studied using NMR and biochemical techniques, and the DNA-binding properties of the compounds are determined using spectrophotometric studies (UV-vis absorption, fluorescence, and circular/linear dichroism) and viscometry. The binding constants K are estimated as being in the range of 2.2 to 7.8×104M-1 and the percentage of hypochromism was found to be 22.11-49.75% (from UV-vis spectral titration). Electrophoretic experiments prove that the novel compounds demonstrate moderate inhibitory effects against Topo I activity at a concentration of 60×10-6M.
Asunto(s)
Acridinas , Tiourea , Inhibidores de Topoisomerasa I , Acridinas/análisis , Acridinas/química , Acridinas/metabolismo , Dicroismo Circular , ADN/química , ADN/metabolismo , ADN-Topoisomerasas de Tipo I , Espectroscopía de Resonancia Magnética , Modelos Moleculares , Espectrofotometría Ultravioleta , Tiosemicarbazonas/análisis , Tiosemicarbazonas/química , Tiosemicarbazonas/metabolismo , Tiourea/análisis , Tiourea/química , Tiourea/metabolismo , Inhibidores de Topoisomerasa I/análisis , Inhibidores de Topoisomerasa I/química , Inhibidores de Topoisomerasa I/metabolismoRESUMEN
Non-reducing iterative type I polyketide synthase genes, pnk1 and pnk2, were cloned from the fungus Phoma sp. BAUA2861, which produces the topoisomerase I inhibitors, topopyrones A to D. Heterologous expression of these polyketide synthase genes under the α-amylase promoter in Aspergillus oryzae was carried out to identify their functions. The pnk2 transformant produced topopyrones C, D, and haematommone. Therefore, the pnk2 gene was found to encode for the topopyrone nonaketide synthase.
Asunto(s)
Ascomicetos/enzimología , Sintasas Poliquetidas/metabolismo , Inhibidores de Topoisomerasa I/análisis , Antraquinonas/análisis , Antraquinonas/metabolismo , ADN-Topoisomerasas de Tipo I/metabolismo , Humanos , Estructura Molecular , Sintasas Poliquetidas/genética , Pironas/análisis , Pironas/metabolismo , Inhibidores de Topoisomerasa I/metabolismoRESUMEN
Methyleugenol is a substituted alkenylbenzene found in several herbs and spices. It is classified by the European Union's Scientific Committee on Food as a genotoxic carcinogen. We addressed the biological mechanism of the genotoxic properties of methyleugenol and its oxidative metabolites. Methyleugenol and the oxidative metabolites significantly enhanced the DNA damage in human colon carcinoma cells (HT29). Methyleugenol did not affect the protein status of γH2AX, a biomarker of DNA double-strand breaks, whereas its metabolites methyleugenol-2',3'-epoxide and 3'-oxomethylisoeugenol significantly increased the cellular phosphorylated H2AX level. Both of these metabolites also showed a significant induction of micronuclei in HT29 cells. Furthermore, we investigated whether topoisomerase interaction contribute to the observed effect on DNA integrity. Methyleugenol-2',3'-epoxide and 3'-oxomethylisoeugenol inhibited the activity of recombinant topoisomerase I. In HT29 cells, neither methyleugenol nor the metabolites affected the level of topoisomerase protein bound to DNA, excluding a topoisomerase poisoning mode of action. In addition, 3'-oxomethylisoeugenol potently diminished the level of camptothecin-stabilized topoisomerase I/DNA intermediates and camptothecin-induced DNA strand breaks. In conclusion, it could be suggested that 3'-oxomethylisoeugenol may also interact with classical or food-borne topoisomerase I poisons, diminishing their poisoning effectiveness.
Asunto(s)
Carcinógenos Ambientales/toxicidad , Neoplasias del Colon/inducido químicamente , Daño del ADN , ADN-Topoisomerasas de Tipo I/metabolismo , Eugenol/análogos & derivados , Mutágenos/toxicidad , Inhibidores de Topoisomerasa I/toxicidad , Biomarcadores de Tumor/agonistas , Biomarcadores de Tumor/metabolismo , Biotransformación , Carcinógenos Ambientales/análisis , Carcinógenos Ambientales/metabolismo , Carcinoma/inducido químicamente , Carcinoma/enzimología , Neoplasias del Colon/enzimología , Neoplasias del Colon/metabolismo , Ensayo Cometa , ADN-Topoisomerasas de Tipo I/química , ADN-Topoisomerasas de Tipo I/genética , Compuestos Epoxi/análisis , Compuestos Epoxi/metabolismo , Compuestos Epoxi/toxicidad , Eugenol/análisis , Eugenol/metabolismo , Eugenol/toxicidad , Contaminación de Alimentos , Células HT29 , Histonas/agonistas , Histonas/metabolismo , Humanos , Pruebas de Micronúcleos , Mutágenos/análisis , Mutágenos/metabolismo , Proteínas de Neoplasias/agonistas , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , Oxidación-Reducción , Fosforilación/efectos de los fármacos , Procesamiento Proteico-Postraduccional/efectos de los fármacos , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Especias/efectos adversos , Especias/análisis , Inhibidores de Topoisomerasa I/análisis , Inhibidores de Topoisomerasa I/metabolismoRESUMEN
A series of new benzimidazole derivatives with potential anticancer activity were tested as a new topoisomerase I inhibitors. The fluorometric method was used to determine in vitro the quantitative level of plasmid DNA relaxation by these compounds. Optimization of the fluorometric system and validation of the established analytical method were performed. Out of benzimidazole derivatives which were analyzed, in the case of five derivatives inhibition of topoisomerase I was greater than camptothecin (compounds 11, 12, 15, 21, 22).
Asunto(s)
Bencimidazoles/síntesis química , Fluorometría/métodos , Inhibidores de Topoisomerasa I/síntesis química , Bencimidazoles/análisis , Inhibidores de Topoisomerasa I/análisisRESUMEN
AIM: To determine intravitreal and plasma concentrations and retinal toxicity after transcorneal intravitreal injection of 1 µg and 2 µg of topotecan (Hycamtin). METHOD: Twelve healthy albino rabbits were included in this in vivo experiment. Six anesthetized albino rabbits received a single transcorneal intravitreal injection of 1 µg (group A) or 2 µg (group B) of topotecan. Vitreous and blood samples were collected until 168 h. Left eyes were treated with the same volume of saline. Plasma and vitreous levels of topotecan were determined by high-performance liquid chromatography. Area under the plasma concentration time curve (AUC) was calculated using trapezoidal rule. Clinical evidence of toxicity was classified into four grades according to anatomical structures. Electroretinograms (ERGs) were recorded. RESULTS: Time to maximum concentration was observed up to 2 h after drug injection in group A whereas up to 1 h in group B. Low levels of topotecan were detected in plasma in both groups and in the vitreous humor of the contralateral eye in group B. Topotecan levels (mean vitreous AUC in group A 2.55 µg/mL.h and in group B 5.338 µg/mL.h) were detectable up to 6 h in both groups. We observed following structural changes in rabbit eyes: corneal vascularization, cataract, hemophthalmus, choroidal edema and focal retinal atrophy. Abnormal ERGs were obtained. CONCLUSION: Our findings proved that transcorneal intravitreal administration of 1 µg and 2 µg of topotecan results in potentially cytotoxic intraocular concentrations. More studies are needed to establish the safety of topotecan for retinoblastoma in children.
Asunto(s)
Retina/efectos de los fármacos , Neoplasias de la Retina/tratamiento farmacológico , Retinoblastoma/tratamiento farmacológico , Inhibidores de Topoisomerasa I/administración & dosificación , Topotecan/administración & dosificación , Cuerpo Vítreo/química , Animales , Conejos , Inhibidores de Topoisomerasa I/análisis , Inhibidores de Topoisomerasa I/sangre , Topotecan/análisis , Topotecan/sangreRESUMEN
PURPOSE: To determine experimentally the intestinal permeability of the anticancer prodrug irinotecan, and to quantify the amount of its cytotoxic metabolite SN-38 that is intestinally excreted (exsorped) as a predictor of intestinal toxicity, and to assess the effect of p-glycoprotein (p-gp) inhibitors (verapamil as a model) on the permeability and toxicity of irinotecan. METHODS: Single pass intestinal perfusion of rat's whole length small intestines is applied to assess the permeability of the parent drug and quantify the intestinally excreted metabolite. The perfusion solution contained 30µg/ml of irinotecan (control group) without or with verapamil (verapamil group). A simple reversed phase HPLC method with UV detection is developed and validated for simultaneous determination of irinotecan and SN-38 using camptothecin as an internal standard. RESULTS: HPLC-UV method found to be simple, specific, accurate, and precise. Effective permeability coefficient of irinotecan found to be 4.9±1.7 10-3 mm/min and was doubled in verapamil group (P=0.007). Average cumulative amount of SN-38 exsorped found to be 29 ng/cm over 2 hours perfusion time which was decreased to 15 ng/cm in verapamil group (P=0.016). CONCLUSIONS: in situ intestinal perfusion method was successfully applied to quantify the permeability of irinotecan and the exsorption of SN-38 in the same experiment, in a manner that robustly reflects real in vivo situation. P-gp inhibition using verapamil found to significantly enhance the intestinal permeability of irinotecan and potentially decrease the intestinal toxicity due to SN-38 exposure.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Camptotecina/análogos & derivados , Cromatografía Líquida de Alta Presión/métodos , Interacciones Farmacológicas , Absorción Intestinal/fisiología , Mucosa Intestinal/metabolismo , Perfusión , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Animales , Calibración , Camptotecina/administración & dosificación , Camptotecina/metabolismo , Camptotecina/farmacocinética , Estabilidad de Medicamentos , Absorción Intestinal/efectos de los fármacos , Intestinos/efectos de los fármacos , Irinotecán , Masculino , Ratas , Ratas Sprague-Dawley , Inhibidores de Topoisomerasa I/análisis , Inhibidores de Topoisomerasa I/química , Inhibidores de Topoisomerasa I/metabolismo , Verapamilo/farmacologíaRESUMEN
The purpose of this work was to encapsulate 7-Ethyl-10-hydroxy-camptothecin (Sn38) in lipid nanocapsules (LNCs) using phase inversion-based method in order to deliver Sn38 by oral route. LNCs were prepared by a low-energy emulsification method and were characterized for size, polydispersity index (PDI), surface charge, drug payload, in vitro drug release, and storage stability. Moreover, in view of an oral administration, in vitro stability in gastrointestinal fluid and permeability across Caco-2 cells were tested. Sn38-loaded LNCs with a mean particle size of 38±2 nm were obtained. The particles displayed a narrow size distribution and a drug payload of 0.40±0.07 mg/g of LNC dispersion. In vitro stability in simulated gastric and intestinal media was also observed. Finally, Sn38-loaded LNCs improved permeability of Sn38 across Caco-2 cells (5.69±0.87×10(6) cm s(-1) at 6h vs 0.31±0.02×10(6) cm s(-1)) and intracellular concentration compared with free Sn38. In conclusion, Sn38 nanocarriers have been developed and display a strong potential for oral administration.